Skip to main content

Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.

Publication ,  Journal Article
Hornik, CP; Herring, AH; Benjamin, DK; Capparelli, EV; Kearns, GL; van den Anker, J; Cohen-Wolkowiez, M; Clark, RH; Smith, PB ...
Published in: Pediatr Infect Dis J
July 2013

BACKGROUND: Carbapenems are commonly used in hospitalized infants despite a lack of complete safety data and associations with seizures in older children. We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin. METHODS: We conducted a retrospective cohort study of 5566 infants treated with meropenem or imipenem/cilastatin in neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2010. Multivariable conditional logistic regression was performed to evaluate the association between carbapenem therapy and adverse events, controlling for infant factors and severity of illness. RESULTS: Adverse events were more common with use of meropenem compared with imipenem/cilastatin (62.8/1000 infant days versus 40.7/1000 infant days, P < 0.001). There was no difference in seizures with meropenem versus imipenem/cilastatin (adjusted odds ratio 0.96; 95% confidence interval: 0.68, 1.32). The incidence of death, as well as the combined outcome of death or seizure, was lower with meropenem use-odds ratio 0.68 (0.50, 0.88) and odds ratio 0.77 (0.62, 0.95), respectively. CONCLUSION: In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Infect Dis J

DOI

EISSN

1532-0987

Publication Date

July 2013

Volume

32

Issue

7

Start / End Page

748 / 753

Location

United States

Related Subject Headings

  • Thienamycins
  • Survival Analysis
  • Seizures
  • Retrospective Studies
  • Pediatrics
  • Meropenem
  • Intensive Care, Neonatal
  • Infant
  • Incidence
  • Imipenem
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hornik, C. P., Herring, A. H., Benjamin, D. K., Capparelli, E. V., Kearns, G. L., van den Anker, J., … Best Pharmaceuticals for Children Act-Pediatric Trials Network. (2013). Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J, 32(7), 748–753. https://doi.org/10.1097/INF.0b013e31828be70b
Hornik, Christoph P., Amy H. Herring, Daniel K. Benjamin, Edmund V. Capparelli, Gregory L. Kearns, John van den Anker, Michael Cohen-Wolkowiez, Reese H. Clark, P Brian Smith, and Best Pharmaceuticals for Children Act-Pediatric Trials Network. “Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.Pediatr Infect Dis J 32, no. 7 (July 2013): 748–53. https://doi.org/10.1097/INF.0b013e31828be70b.
Hornik CP, Herring AH, Benjamin DK, Capparelli EV, Kearns GL, van den Anker J, et al. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J. 2013 Jul;32(7):748–53.
Hornik, Christoph P., et al. “Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.Pediatr Infect Dis J, vol. 32, no. 7, July 2013, pp. 748–53. Pubmed, doi:10.1097/INF.0b013e31828be70b.
Hornik CP, Herring AH, Benjamin DK, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB, Best Pharmaceuticals for Children Act-Pediatric Trials Network. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J. 2013 Jul;32(7):748–753.

Published In

Pediatr Infect Dis J

DOI

EISSN

1532-0987

Publication Date

July 2013

Volume

32

Issue

7

Start / End Page

748 / 753

Location

United States

Related Subject Headings

  • Thienamycins
  • Survival Analysis
  • Seizures
  • Retrospective Studies
  • Pediatrics
  • Meropenem
  • Intensive Care, Neonatal
  • Infant
  • Incidence
  • Imipenem